Comparison of the efficacy of rechallenge with anti-PD-1 antibody monotherapy and BRAF/MEK inhibitor in advanced malignant melanoma: A single-center, retrospective cohort study

Comparison of the efficacy of rechallenge with anti-PD-1 antibody monotherapy and BRAF/MEK inhibitor in advanced malignant melanoma: A single-center, retrospective cohort study

Anti-PD-1 antibody monotherapy (anti-PD-1) and BRAF/MEK inhibitors (BRAF/MEKi) are currently recognized as effective treatments for advanced-stage malignant melanoma (MM) and have become standard systemic treatments. However, many patients with MM still do not benefit from these therapies. In this s...

Full description

Saved in:
Bibliographic Details
Main Authors: Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, Arata Tsutsumida, Yoshio Kiyohara
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2025-04-01
Series:Dermatologica Sinica
Subjects:
braf/mek inhibitor
immune check point inhibitor
melanoma
rechallenge
Online Access:https://journals.lww.com/10.4103/ds.DS-D-25-00005
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://journals.lww.com/10.4103/ds.DS-D-25-00005

Similar Items